SYRS (Syros Pharmaceuticals) Other Stockholders Equity: $0.00 Mil (As of Sep. 2024)


SYRS Syros Pharmaceuticals Inc SYRS
12 GF Score
Price $0.00
View Full Analysis

What is Syros Pharmaceuticals Other Stockholders Equity?

Syros Pharmaceuticals SYRS 12 Other Stockholders Equity is $0.00 Mil as of Sep. 2024. GuruFocus rates SYRS with a GF Score™ of 12/100.

Syros Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Sep. 2024 was $0.00 Mil.

Syros Pharmaceuticals's quarterly Other Stockholders Equity declined from Mar. 2024 ($-0.00 Mil) to Jun. 2024 ($-0.00 Mil) but then increased from Jun. 2024 ($-0.00 Mil) to Sep. 2024 ($0.00 Mil).

Syros Pharmaceuticals's annual Other Stockholders Equity declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($-0.00 Mil) but then increased from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil).

Syros Pharmaceuticals Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Syros Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syros Pharmaceuticals Other Stockholders Equity Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 -0.00 0.00

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 -0.00 0.00
SYRS
12GF Score
Syros Pharmaceuticals Inc SYRS
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syros Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
Syros Pharmaceuticals (SYRS) has a Other Stockholders Equity of $0.00 Mil as of Sep. 2024. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Syros Pharmaceuticals and its competitors.
Is Syros Pharmaceuticals' Other Stockholders Equity too high?
Syros Pharmaceuticals' current Other Stockholders Equity is $0.00 Mil. Overall, Syros Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Syros Pharmaceuticals' Other Stockholders Equity compare to AFMDQ and BTAX?
Syros Pharmaceuticals' Other Stockholders Equity of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Syros Pharmaceuticals and its competitors. Syros Pharmaceuticals's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syros Pharmaceuticals stock overvalued right now?
Syros Pharmaceuticals (SYRS) has a current Other Stockholders Equity of $0.00 Mil. The current Other Stockholders Equity is $0.00 Mil. Syros Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Syros Pharmaceuticals (SYRS), the current Other Stockholders Equity is $0.00 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syros Pharmaceuticals Business Description

Address 35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
12GF Score

Get the complete analysis for SYRS

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price